Research led by the SKiN Center for Dermatology observed substantial clearance of scalp and body psoriasis and rapid itch ...

Johnson & Johnson (JNJ) posts promising late-stage trial data for plaque psoriasis icotrokinra developed with Protagonist ...

Using an existing steroid-free topical foam daily significantly improved the signs and symptoms of psoriasis on the scalp and ...

1 Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that ...

Shares of Johnson & Johnson (JNJ) were in the spotlight on Friday morning after the company announced positive results from ...

(Reuters) -Johnson & Johnson said on Friday its experimental psoriasis drug helped patients achieve clear or almost clear ...

Arcutis Biotherapeutics (ARQT) announced that the Journal of American Medical Association Dermatology published the results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE ...

More than half of these individuals experience scalp involvement ... a PDUFA action date for ZORYVE foam 0.3% for treating plaque psoriasis on May 22, 2025. Jefferies also pointed to ARQ-255 ...

He also had scaling plaques on his scalp. He had not been treated previously ... A clinical diagnosis was made of psoriasis and he was prescribed clobetasol propionate ointment with salicylic ...

Results from the separate SCALP study, involving 102 patients with moderate-to-severe scalp psoriasis, showed a significantly higher proportion of patients receiving Cosentyx had 90% plaque ...

Q1 2025 net product revenue for ZORYVE® (roflumilast) was $63.8 million, a 196% increase compared to Q1 of 2024, and a 2% decrease compared to Q4 of 2024, due to typical first-quarter deductible reset ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...